Boom. It really seems like the high TGs are the symptom of something else more important going wrong.
I agree that this is probably true - the APOC3 trials by IONS had surprising results on glucose control. Anyone who was paying attention was surprised that something that was expected to only directly influence lipids had a dramatic effect on glucose. (and I give the CEO a lot of credit for really focusing the Ph2s on this - so he'd know.)
And part of the reason I watch AMRN is because I am interested in this nexus - i.e. I will be interested in all the secondary endpoints for the Vascepa ph3.
That said, of course I think the trial has a LOT of risk. In a way very similar to ONTY - I think it likely it has some interesting benefit somewhere, but probably not enough on the primary endpoint (or has enough side effects to cause it not to be worthwhile.).